Although more than 40 patent applications on small-molecule drug candidates targeting RIP1 have been published since 2016, to date, only a few of this class of inhibitors have been or are already being tested in the clinic, e.g., in rheumatoid arthritis, psoriasis, ulcerative colitis, neurodegenerative diseases (AD or ALS) and severe COVID-19 lung disease [67]. This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.